ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Respiratory Syncytial Virus Vaccine for the Elderly Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-30K17808
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Respiratory Syncytial Virus Vaccine for the Elderly Market Research Report 2024
BUY CHAPTERS

Global Respiratory Syncytial Virus Vaccine for the Elderly Market Research Report 2024

Code: QYRE-Auto-30K17808
Report
August 2024
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Icosavax
Daiichi Sankyo
Pfizer Inc
GSK
Vendors
Moderna, Inc
Sanofi
Advaccine
Immorna
Blue Lake Biotechnology
Starna Therapeutics
Clover Biopharma
Innorna
RNAimmune

Respiratory Syncytial Virus Vaccine for the Elderly Market

The global Respiratory Syncytial Virus Vaccine for the Elderly market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly include GSK, Pfizer, Moderna, Daiichi Sankyo, Icosavax, Sanofi, Blue Lake Biotechnology, Advaccine, Starna Therapeutics, Immorna, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Respiratory Syncytial Virus Vaccine for the Elderly, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Syncytial Virus Vaccine for the Elderly.
The Respiratory Syncytial Virus Vaccine for the Elderly market size, estimations, and forecasts are provided in terms of sales volume (Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Respiratory Syncytial Virus Vaccine for the Elderly market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Syncytial Virus Vaccine for the Elderly manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Respiratory Syncytial Virus Vaccine for the Elderly Market Report

Report Metric Details
Report Name Respiratory Syncytial Virus Vaccine for the Elderly Market
Segment by Type
Segment by Application
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GSK, Pfizer, Moderna, Daiichi Sankyo, Icosavax, Sanofi, Blue Lake Biotechnology, Advaccine, Starna Therapeutics, Immorna, Clover Biopharma, Innorna, RNAimmune
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Respiratory Syncytial Virus Vaccine for the Elderly in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Respiratory Syncytial Virus Vaccine for the Elderly Market report?

Ans: The main players in the Respiratory Syncytial Virus Vaccine for the Elderly Market are GSK, Pfizer, Moderna, Daiichi Sankyo, Icosavax, Sanofi, Blue Lake Biotechnology, Advaccine, Starna Therapeutics, Immorna, Clover Biopharma, Innorna, RNAimmune

What are the Application segmentation covered in the Respiratory Syncytial Virus Vaccine for the Elderly Market report?

Ans: The Applications covered in the Respiratory Syncytial Virus Vaccine for the Elderly Market report are Hospital, Centers for Disease Control and Prevention, Others

What are the Type segmentation covered in the Respiratory Syncytial Virus Vaccine for the Elderly Market report?

Ans: The Types covered in the Respiratory Syncytial Virus Vaccine for the Elderly Market report are Recombinant Protein Vaccine, Nucleic Acid Vaccines, Others

Recommended Reports

Human Vaccine Markets

Respiratory Diseases

Influenza & Viral

1 Respiratory Syncytial Virus Vaccine for the Elderly Market Overview
1.1 Product Definition
1.2 Respiratory Syncytial Virus Vaccine for the Elderly by Type
1.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Value Comparison by Type (2024-2030)
1.2.2 Recombinant Protein Vaccine
1.2.3 Nucleic Acid Vaccines
1.2.4 Others
1.3 Respiratory Syncytial Virus Vaccine for the Elderly by Application
1.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Centers for Disease Control and Prevention
1.3.4 Others
1.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Estimates and Forecasts
1.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2019-2030
1.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales 2019-2030
1.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Respiratory Syncytial Virus Vaccine for the Elderly Market Competition by Manufacturers
2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Manufacturers (2019-2024)
2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Respiratory Syncytial Virus Vaccine for the Elderly, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Product Type & Application
2.7 Global Key Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Date of Enter into This Industry
2.8 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Competitive Situation and Trends
2.8.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Respiratory Syncytial Virus Vaccine for the Elderly Players Market Share by Revenue
2.8.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Scenario by Region
3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2019-2030
3.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2019-2024
3.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2025-2030
3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2019-2030
3.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2019-2024
3.3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2025-2030
3.4 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
3.4.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2030)
3.4.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
3.5.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2030)
3.5.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Region
3.6.1 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2019-2030)
3.6.3 Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
3.7.1 Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2030)
3.7.3 Latin America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Facts & Figures by Country
3.8.1 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2030)
3.8.3 Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2019-2030)
4.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2019-2024)
4.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2025-2030)
4.1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2019-2030)
4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2019-2030)
4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2019-2024)
4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2025-2030)
4.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2019-2030)
4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2019-2030)
5 Segment by Application
5.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2019-2030)
5.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2019-2024)
5.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2025-2030)
5.1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2019-2030)
5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2019-2030)
5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2019-2024)
5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2025-2030)
5.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2019-2030)
5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Moderna
6.3.1 Moderna Company Information
6.3.2 Moderna Description and Business Overview
6.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.3.5 Moderna Recent Developments/Updates
6.4 Daiichi Sankyo
6.4.1 Daiichi Sankyo Company Information
6.4.2 Daiichi Sankyo Description and Business Overview
6.4.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.4.5 Daiichi Sankyo Recent Developments/Updates
6.5 Icosavax
6.5.1 Icosavax Company Information
6.5.2 Icosavax Description and Business Overview
6.5.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.5.5 Icosavax Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Company Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Blue Lake Biotechnology
6.7.1 Blue Lake Biotechnology Company Information
6.7.2 Blue Lake Biotechnology Description and Business Overview
6.7.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.7.5 Blue Lake Biotechnology Recent Developments/Updates
6.8 Advaccine
6.8.1 Advaccine Company Information
6.8.2 Advaccine Description and Business Overview
6.8.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.8.5 Advaccine Recent Developments/Updates
6.9 Starna Therapeutics
6.9.1 Starna Therapeutics Company Information
6.9.2 Starna Therapeutics Description and Business Overview
6.9.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.9.5 Starna Therapeutics Recent Developments/Updates
6.10 Immorna
6.10.1 Immorna Company Information
6.10.2 Immorna Description and Business Overview
6.10.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.10.5 Immorna Recent Developments/Updates
6.11 Clover Biopharma
6.11.1 Clover Biopharma Company Information
6.11.2 Clover Biopharma Description and Business Overview
6.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.11.5 Clover Biopharma Recent Developments/Updates
6.12 Innorna
6.12.1 Innorna Company Information
6.12.2 Innorna Description and Business Overview
6.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.12.5 Innorna Recent Developments/Updates
6.13 RNAimmune
6.13.1 RNAimmune Company Information
6.13.2 RNAimmune Description and Business Overview
6.13.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue and Gross Margin (2019-2024)
6.13.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
6.13.5 RNAimmune Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Chain Analysis
7.2 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process
7.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales and Marketing
7.4.1 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels
7.4.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
7.5 Respiratory Syncytial Virus Vaccine for the Elderly Customers
8 Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
8.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
8.2 Respiratory Syncytial Virus Vaccine for the Elderly Market Drivers
8.3 Respiratory Syncytial Virus Vaccine for the Elderly Market Challenges
8.4 Respiratory Syncytial Virus Vaccine for the Elderly Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Icosavax
Daiichi Sankyo
Pfizer Inc
GSK
Vendors
Moderna, Inc
Sanofi
Advaccine
Immorna
Blue Lake Biotechnology
Starna Therapeutics
Clover Biopharma
Innorna
RNAimmune
List of Tables
 Table 1. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) of Key Manufacturers (2019-2024)
 Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Respiratory Syncytial Virus Vaccine for the Elderly Average Price (US$/Dose) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Respiratory Syncytial Virus Vaccine for the Elderly, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Product Type & Application
 Table 12. Global Key Manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Respiratory Syncytial Virus Vaccine for the Elderly by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Syncytial Virus Vaccine for the Elderly as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2019-2024) & (Dose)
 Table 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2019-2024)
 Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2025-2030) & (Dose)
 Table 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2025-2030)
 Table 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2019-2024)
 Table 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2025-2030)
 Table 25. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2024) & (Dose)
 Table 27. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2025-2030) & (Dose)
 Table 28. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2024) & (Dose)
 Table 32. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2025-2030) & (Dose)
 Table 33. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2019-2024) & (Dose)
 Table 37. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2025-2030) & (Dose)
 Table 38. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2024) & (Dose)
 Table 42. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2025-2030) & (Dose)
 Table 43. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2019-2024) & (Dose)
 Table 47. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2025-2030) & (Dose)
 Table 48. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Type (2019-2024)
 Table 51. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Type (2025-2030)
 Table 52. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2019-2024)
 Table 53. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2025-2030)
 Table 54. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2019-2024)
 Table 57. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2025-2030)
 Table 58. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Dose) by Type (2019-2024)
 Table 59. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Dose) by Type (2025-2030)
 Table 60. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Application (2019-2024)
 Table 61. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose) by Application (2025-2030)
 Table 62. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2019-2024)
 Table 63. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2025-2030)
 Table 64. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2019-2024)
 Table 67. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2025-2030)
 Table 68. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Dose) by Application (2019-2024)
 Table 69. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Dose) by Application (2025-2030)
 Table 70. GSK Company Information
 Table 71. GSK Description and Business Overview
 Table 72. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 73. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 74. GSK Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 78. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Moderna Company Information
 Table 81. Moderna Description and Business Overview
 Table 82. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 83. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 84. Moderna Recent Developments/Updates
 Table 85. Daiichi Sankyo Company Information
 Table 86. Daiichi Sankyo Description and Business Overview
 Table 87. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 88. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 89. Daiichi Sankyo Recent Developments/Updates
 Table 90. Icosavax Company Information
 Table 91. Icosavax Description and Business Overview
 Table 92. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 93. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 94. Icosavax Recent Developments/Updates
 Table 95. Sanofi Company Information
 Table 96. Sanofi Description and Business Overview
 Table 97. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 98. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 99. Sanofi Recent Developments/Updates
 Table 100. Blue Lake Biotechnology Company Information
 Table 101. Blue Lake Biotechnology Description and Business Overview
 Table 102. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 103. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 104. Blue Lake Biotechnology Recent Developments/Updates
 Table 105. Advaccine Company Information
 Table 106. Advaccine Description and Business Overview
 Table 107. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 108. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 109. Advaccine Recent Developments/Updates
 Table 110. Starna Therapeutics Company Information
 Table 111. Starna Therapeutics Description and Business Overview
 Table 112. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 113. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 114. Starna Therapeutics Recent Developments/Updates
 Table 115. Immorna Company Information
 Table 116. Immorna Description and Business Overview
 Table 117. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 118. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 119. Immorna Recent Developments/Updates
 Table 120. Clover Biopharma Company Information
 Table 121. Clover Biopharma Description and Business Overview
 Table 122. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 123. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 124. Clover Biopharma Recent Developments/Updates
 Table 125. Innorna Company Information
 Table 126. Innorna Description and Business Overview
 Table 127. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 128. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 129. Innorna Recent Developments/Updates
 Table 130. RNAimmune Company Information
 Table 131. RNAimmune Description and Business Overview
 Table 132. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 133. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product
 Table 134. RNAimmune Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List
 Table 138. Respiratory Syncytial Virus Vaccine for the Elderly Customers List
 Table 139. Respiratory Syncytial Virus Vaccine for the Elderly Market Trends
 Table 140. Respiratory Syncytial Virus Vaccine for the Elderly Market Drivers
 Table 141. Respiratory Syncytial Virus Vaccine for the Elderly Market Challenges
 Table 142. Respiratory Syncytial Virus Vaccine for the Elderly Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Respiratory Syncytial Virus Vaccine for the Elderly
 Figure 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Type: 2023 & 2030
 Figure 4. Recombinant Protein Vaccine Product Picture
 Figure 5. Nucleic Acid Vaccines Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Value by Application (2024-2030) & (US$ Million)
 Figure 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Application: 2023 & 2030
 Figure 9. Hospital
 Figure 10. Centers for Disease Control and Prevention
 Figure 11. Others
 Figure 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size (2019-2030) & (US$ Million)
 Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2019-2030) & (Dose)
 Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Average Price (US$/Dose) & (2019-2030)
 Figure 16. Respiratory Syncytial Virus Vaccine for the Elderly Report Years Considered
 Figure 17. Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Manufacturers in 2023
 Figure 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Manufacturers in 2023
 Figure 19. Global 5 and 10 Largest Respiratory Syncytial Virus Vaccine for the Elderly Players: Market Share by Revenue in Respiratory Syncytial Virus Vaccine for the Elderly in 2023
 Figure 20. Respiratory Syncytial Virus Vaccine for the Elderly Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 22. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2019-2030)
 Figure 23. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2019-2030)
 Figure 24. United States Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2019-2030)
 Figure 27. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2019-2030)
 Figure 28. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2019-2030)
 Figure 34. Asia Pacific Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2019-2030)
 Figure 35. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. Australia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. China Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2019-2030)
 Figure 43. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Colombia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2019-2030)
 Figure 48. Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2019-2030)
 Figure 49. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. UAE Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Global Sales Market Share of Respiratory Syncytial Virus Vaccine for the Elderly by Type (2019-2030)
 Figure 53. Global Revenue Market Share of Respiratory Syncytial Virus Vaccine for the Elderly by Type (2019-2030)
 Figure 54. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Dose) by Type (2019-2030)
 Figure 55. Global Sales Market Share of Respiratory Syncytial Virus Vaccine for the Elderly by Application (2019-2030)
 Figure 56. Global Revenue Market Share of Respiratory Syncytial Virus Vaccine for the Elderly by Application (2019-2030)
 Figure 57. Global Respiratory Syncytial Virus Vaccine for the Elderly Price (US$/Dose) by Application (2019-2030)
 Figure 58. Respiratory Syncytial Virus Vaccine for the Elderly Value Chain
 Figure 59. Respiratory Syncytial Virus Vaccine for the Elderly Production Process
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Respiratory Syncytial Virus Vaccine for Children Market Research Report 2024
Global Vaccines for the Elderly Market Research Report 2024
Respiratory Syncytial Virus Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Respiratory Virus Vaccines Market Research Report 2024
Global Respiratory Syncytial Virus Therapeutic Drugs Market Research Report 2024
Global Children Respiratory Syncytial Virus Therapeutics Market Research Report 2024
Anti Respiratory Syncytial Virus Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Respiratory Syncytial Virus Treatment Market Research Report 2024
Pediatric Respiratory Syncytial Virus Infection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
RSV Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Respiratory Syncytial Virus Diagnostic Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Respiratory Syncytial Virus RSV Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Respiratory Syncytial Virus RSV Infections Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Adult Vaccines Market Research Report 2024
Global Respiratory Syncytial Virus RSV Antigen and Antibody Reagent Market Research Report 2024
Global Respiratory Syncytial Virus Fusion Protein Drug Market Research Report 2024
Respiratory Syncytial Virus RSV Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Streptococcus Pneumoniae Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Viral Arthritis Vaccine Market Research Report 2025
Global Pneumococcal Polysaccharide Vaccine Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions